5[5]Giakkoupi P. Tzouvelekis L S, Tsakris A, et al. IBC-1,a novel integon-associated class A beta-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain[J]. Agents Chemother, 2000, 44(9): 2247-2249.
6[6]Poirel L, Le Thomas I, Naas T, et al. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and class 1 integron In52 from Klebsiella pneumoniae[J]. Antimicrob Agents Chemother, 2000, 44(3): 622-623.
7[7]Bonnet R, Ssmpaio J L, Chanal C, et al. A novel class A extended-spectrum beta-lactamase (ESBLs) in Serratia marcescens isolated in Brazil[J]. Antimicrob Agents Chemother, 2000, 44(11): 3061-3064.
8[8]National Committee for Clinical Laboratory Standards Performance Standards for antimicrobial susceptibility testing: with informational supplement[S]. NCCLS documents M100-S9 pennsylvania: NCCLS, 1999. 17-19.
9[9]Vercauteren E, Descheemaeker P, Leven M, et al. Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian Teaching Hospital[J]. Clin Microbiol, 1997, 35(9): 2191-2197.
10[10]Liu PYF, Tung JC, Ke SC. Molecular epidemiology of extended-spectrum β-lactamases-prouducing Klebsiella pneumoniae isolates in a district hospital in Taiwan[J]. Clin Microbio, 1998, 36: 2759-2762.
二级参考文献16
1Mcmanus MC. Mechanism of bacterial resistance to antimicrobial agent[J]. AM J Health Syst Pharm, 1997,54 (12) :1420-1433.
2Cappelletty D. Microbiology of bacterial respiratory infections[J]. Pediatr Infect Dis J, 1998,17 (8 Suppl): S55-61.
3Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria[J]. Clin Infect Dis,1998,27(Suppl 1) :S93-99.
4Szabo D, Barcs I, Rozgonyi F. Extended-spectrum betalactamases:an actual problem of hospital microbiology[J].Acta Microbiol Immunol Hung, 1997,44 (4): 309-325.
5Rotschafer JC, Ostergaard BE. Combination Beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition [J]. Am J Health Syst Pharm, 1995, 52 (6 Suppl 2):S15-22.
7Philippon A, Dusart J, Joris B, et al.The div ersity, structure and regula tion of beta-lactamases [J]. Cell Mol Life Science, 1998,54(4) :341-346.
8Culebras E, Martez JL. Aminoglycoside resistance mediated by the bifunctional enzyme 6 ′-N-aminoglycoside acetyltransferase-2"-O-aminoglycoside phosphotransferase[J]. Front Biosci,1999,4:D1-8.
9Brakstad OG, Maeland JA. Mechanisms of methicillin resistance in staphylococci[J]. APMIS, 1997, 105(4) :264 276.
10Livermore DM. Beta-lactamase-mediated resistance and opportunities for its control [J]. J Antimicrob Chemother, 1998,41 (Suppl D): 25-41.
6Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother, 1995, 39(6): 1211-1233.
